Galderma Group AG
🇨🇭Switzerland
FDA's new drug approvals in August include a Dupixent competitor, a targeted glioma ...
FDA approved seven new therapies in August, including a competitor to Dupixent for prurigo nodularis, Gilead’s PPARδ agonist, and targeted cancer therapies.
© Copyright 2024. All Rights Reserved by MedPath